RAC - Charts & Price Action, page-1912

I certainly have nothing against the old holders and many of our most supportive shareholders are those that came in long before me. Many of our long term holders have looked carefully at the new strategy and direction of the company and bought many more shares on market.

Everyone who has bought is contributing to the success of RAC, not just those that have participated in raises. As our aim is to do a commercial transaction off the back of high quality clinical data, the size of any deal is going to be determined to a large extent by our SP. We are not going to be able to achieve a high price if our SP is for example down at 10c since any potential acquirer is just going to make a TO offer for 15c and the majority of the shareholders will accept. In biotech, success creates success.